If you haven’t gotten the memo yet, medical psychedelics are the next big thing, and there are great reasons why, that mare made clear through medical testing every day. To give an idea of just how quickly this is now happening, the mushrooms company Levitee Labs has just entered the Canadian Securities Exchange. What does this mean?
It’s not hard to tell medical psychedelics are on their way, with the inclusion of a mushrooms company in the Canadian Securities Exchange. It’s a story we know well from the current situation of fighting for legalization of cannabis, and all included products like delta-8 THC, THCV, and THCA. More legalizations means more products, and this is great for you. We can’t wait until we can offer you psychedelics, but for now, take a look at our delta 10, THC-O, THCV & delta-8 THC deals, and the rest of the compounds we have on offer, to find something that works well for you.
Medical psychedelics have been on the rise for several years, with esketamine legalized in 2019 in the US for use with treatment resistant depression and suicidal thoughts (updated 2020), and research on the way to legalize MDMA and psilocybin from magic mushrooms, complete with ‘breakthrough therapy’ status from the US’s FDA. This makes it not that shocking that a country that already legalized recreational cannabis, would be one of the first to allow a company interested in psychedelics into a securities exchange, and that’s exactly what happened.
What mushrooms company just entered the Canadian Securities Exchange?
On July 19th, 2021, it was announced that integrative medicine company Levitee Labs, Inc., a producer of mushrooms and associated products, would enter the Canadian Securities Exchange on July 21st 2021, which it did, with a starting share price of $.50. This makes it the very first company geared toward the growth and sale of medicinal mushrooms to enter any global exchange. Which is obviously big news if you follow the expanding world of medical psychedelics, as this now makes it an acceptable route.
Levitee is now traded under ‘LVT’, after it announced that it received final approval from the CSE (Canadian Securities Exchange). Levitee operates under two names: Sporeo Supply, which offers premium cultivation feedstock for mushrooms, based out of a facility in British Columbia, and Monk-E Nutraceuticals, which focuses on a line of nutraceutical supplements based on mushrooms, as well as supplies for cultivating mushrooms. It currently works with non-psychedelic mushrooms, but is looking to include the psychedelic counterpart, and is currently working on a psychedelic mushroom product, as per its own site. While its products can be used to grow psychedelic mushrooms, as well as non-psychedelic, it is not the intent of the company for its products to be used for anything illegal. The company has already raised over $12 million CAD through private offerings.